Laboratory adverse events and discontinuation of therapy according to CD4+ cell count at the start of antiretroviral therapy
Sophie José(NHS England), Sarah Fidler(NIHR Imperial Biomedical Research Centre), Martin Fisher(Northwell Health), Killian Quinn(Imperial College London), Frank A. Post(King's College Hospital NHS Foundation Trust), Clifford Leen, Richard Gilson(University College London), Caroline Sabin(Primary Health Care), Margaret Johnson(Duke University), Phillip Hay(Northwick Park Hospital), Mark Nelson(University of Tasmania), Teresa Hill, Mark Gompels, David Chadwick(Lancaster University), John Walsh(Krirk University)
Cited by 11
Related Papers
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
|Hepatology|2006|4.8k
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
|AIDS|2003|987